#16
|
||||
|
||||
Öèòàòà:
ÿ íå óâèäåë (ìîæåò íå çàìåòèë) àíàëèçû ñåðîëîãè÷åñêèå íà öåëèàêèþ è àíàëèçû äëÿ èñêëþ÷åíèÿ àóòîèìóííîãî ãåïàòèòà(Àíòèíóêëåàðíûå àíòèòåëà, àíòèòåëà ïðîòèâ ãëàäêèõ ìûøö...) |
#17
|
|||
|
|||
Âðà÷ îòìåòàåò íàñòîé÷èâî öåëèàêèþ. Ïðî âòîðîé àíàëèç ñïðîøó ó âðà÷à,ñïàñèáî! À âñå òàêè íà ïåðåíåñåííûé ãåïàòèò ñäàâàòü íå íóæíî? Âðà÷ ãîâîðèò ÷òî âñå ãåïàòèòû ýòî îñòðàÿ èíôåêöèÿ,ïîýòîìó íå èìååò ñìûñëà ýòî ïðîâåðÿòü.
|
#18
|
|||
|
|||
ÀÒ ê ÄÍÊ è ÀÒ àíòèÿäåðíûå-ýòî íå àíòèíóêëåàðíûå? Åñëè ýòî îíî,òî ýòî âñå â íîðìå.
|
#19
|
||||
|
||||
Îíè âðîäå.Àíàëèç íà ïåðåíåñåííûé ãåïàòèò À ñäàâàòü íå äóìàþ, ÷òî íóæíî
|
#20
|
|||
|
|||
Äîáðûé äåíü! Âû êîãäà-íèáóäü ñäàâàëè êðîâü íà ÊÔÊ (êðåàòèíêèíàçà, êðåàòèíôîñôîêèíàçà)?
Òàêèå ðåçóëüòàòû ìîãóò áûòü ïðè ìèîïàòèè.
__________________
Ñ óâàæåíèåì, Êëàâäèÿ Ê. |
#21
|
|||
|
|||
__________________
Ñ óâàæåíèåì, Êëàâäèÿ Ê. |
#22
|
|||
|
|||
Êðèïòîãåííûé ãåïàòèò
Öèòàòà:
|
|
#23
|
|||
|
|||
Òàêæå ïðèêðåïëÿþ ïîñëåäíþþ âûïèñêó ñ ÍÖÇÄ Ìîñêâû
|
#24
|
||||
|
||||
íå ñïåöèàëèñò, íî áèîïñèÿ ïîõîæà íà ïåðâûé òèï ãëèêîãåíîçà â øàòàõ è äð. ñòðàíàõ èçìåðÿþò àêòèâíîñòü äàííîãî ôåðìåíòà èç ïå÷åí. áèîïòàòà:
Laboratory Initial laboratory findings that are consistent with GSD I include hypoglycemia, lactic acidosis, hyperuricemia, hypercholesterolemia, hypertriglyceridemia, and, in GSD type Ib, abnormalities in neutrophils. In addition, some patients may have been evaluated for other causes of hypoglycemia with glucagon stimulation. A glucagon stimulation test may lead to worsening of the metabolic acidosis in GSD I and therefore is not recommended to make the diagnosis of GSD I. If it is performed, very close monitoring is required due to the risk of acute acidosis and decompensation. In GSD I there will be a significant increase in blood lactate but little or no increase in BG concentration. Biochemical analysis of liver sample. Hepatomegaly often leads gastroenterologists to perform a biopsy of the liver to differentiate among the diverse etiologies of hepatomegaly. It should be emphasized that biopsies are not necessary when GSD is suspected, because gene sequencing is now available for individual disorders as well as panels of relevant genes. Biopsies should lead to a definitive diagnosis in most cases but are critically dependent on correct processing of the tissue. Tissues should be processed for light microscopy and electron microscopy and also should be snap-frozen (~15 mg) in the operating room in liquid nitrogen for biochemical analysis. Usually 30–40 mg of tissue or four cores of liver tissue are required for all the studies necessary to make a definitive diagnosis. In the United States, reliable enzymatic analysis is available on frozen liver biopsy samples. Liver histology can help differentiate GSD I from other hepatic forms of GSD. Histopathological findings of the liver in GSD I include distention of the liver cells by glycogen and fat and the finding that glycogen is uniformly distributed.77 The amount of glycogen accumulation may be normal or only modestly increased. Lipid vacuoles are large and numerous.77 By contrast, in most patients with GSD III, the liver biopsy demonstrates a vacuolar accumulation of non–membrane bound glycogen primarily located in the cytoplasm. Lipid vacuoles are far less numerous in GSD III than in GSD I. The presence of fibrosis, ranging from minimal periportal fibrosis to micronodular cirrhosis, occurs in GSD III, GSD VI, and GSD IX but not in GSD I.18,77,78 Periportal fibrosis is a very early finding in GSD III. In both GSD I and GSD III, the stored material is within the cytoplasm, periodic acid schiff positive, and diastase sensitive. In GSD I, the total glycogen content is much lower than in GSD III, GSD IV, GSD VI, and GSD IX. Clinical assays measure overall G6Pase enzyme activity in liver tissue samples (see description above). Normal G6Pase enzyme activity level in liver is 3.50 ± 0.8 µmol/min/g tissue. In most individuals with GSD Ia, the G6Pase enzyme activity is less than 10% of normal. However, in rare affected individuals with milder clinical manifestations, the G6Pase enzyme activity can be higher (>1.0 and <2.7 µmol/min/g tissue). G6P translocase activity in vitro is difficult to measure in frozen liver biopsy specimens; fresh (unfrozen) liver biopsy tissue is needed to assay enzyme activity accurately. As a result, most clinical diagnostic laboratories do not offer enzyme activity testing for GSD Ib. Molecular genetic testing. Noninvasive molecular genetic testing through full gene sequencing of the G6PC (GSD Ia) and SLC37A4 (GSD Ib) genes can be used for confirming the diagnosis.79 Mutations in the G6PC gene are responsible for ~80% of GSD I cases... [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#25
|
|||
|
|||
Ïðèêðåïëÿþ åùå îäíó ãåíåòèêó,òàì èñêëþ÷åíû âñå ãëèêîãåíîçû🤷🏼♀ è åùå íåêîòîðûå áîëåçíè íàêîïëåíèÿ êàê ôðóêòîçåìèÿ è òä. Äóìàþ åñòü ëè ñìûñë ïåðåñìîòðåòü áèîïñèþ?
|
#26
|
||||
|
||||
Âàì îñòàâëþ åùå îäíó ïóáëèêàöèþ èç Èðàíà - òàì ãëàâíîå áûëî áèîïñèÿ ïå÷åíè è òèïè÷íûå íàõîäêè, íî ó îòäåëüíûõ äåòåé áûëè àáñîëþòíî íîâûå ìóòàöèè è ó îäíîãî ðåáåíêà âîîáùå íè÷åãî íå íàøëè â ãåíåòèêå, íî êëèíè÷åñêè è íà áèîïñèè áûë ãëèêîãåíîç, ðåáåíîê æå íå áûë ðîæäåí îò áëèçêîðîäñòâåííîãî áðàêà? íàöèîíàëüíîñòü ðåáåíêà ìîæåòå óòî÷íèòü? àøêåíàçñêàÿ èëè èíàÿ åâðåéñêàÿ ïðèíàäëåæíîñòü íå èñêëþ÷àåòñÿ?
Clinical and genetic spectrum of glycogen storage disease in Iranian population using targeted gene sequencing [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#27
|
||||
|
||||
ïðî÷òèòå èíôó èç èðàíà âûøå, â ïðåä. çàêëþ÷åíèè åñòü óêàçàíèå, ÷òî íå îáíàðóæåíû èçâåñòíûå ïàòîãåííûå ìóòàöèè, ñîìíèòåëüíûå íàõîäêè ÍÅ âêëþ÷åíû, â èðàíñêîé áûëè ìóòàöèè íèêîãäà ðàíåå íå îáíàðóæèâàåìûå
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#28
|
|||
|
|||
Ñïàñèáî,ÿ ïðî÷òó. Íàöèîíàëüíîñòü ðóññêèé, áðàê íå ðîäñòâåííûé. Íàø âðà÷ â ÍÖÇÄ ñðàçó ïðåäïîëîæèëà ãëèêîãåíîç,íî óæå äâà ãåíåòè÷åñêèõ àíàëèçà ýòî îïðîâåðãëè. Âðà÷ î÷åíü óäèâèëàñü.ß ñåé÷àñ åùå õî÷ó çàïðîñèòü «ñûðûå äàííûå» ãåíîìà. Êàê äóìàåòå òàì âîçìîæíî óâèäåòü ýòè íåèçó÷åííûå ïîëîìêè íàïðèìåð?
|
#29
|
||||
|
||||
ïîñìîòðèòå îïèñàíèå ñëó÷àÿ çäåñü è ôîòî - êóêîëüíîå ëèöî ñ îêð. ùåêàìè, âñå òå æå îòêëîíåíèÿ, ÷òî ó âàøåãî ðåáåíêà, ôåðìåíòû, hypoglycemia, hypercholesterolemia, hypertriglyceridemia, hyperuricemia, hypercalcemia è òï, òåæå ãèñòî-íàõîäêè è êàðòèíêè - ãåíåòèêó íå äåëàëè, òàê êàê íå íàøëè ñðåäñòâ:
Glycogen Storage Disease Type I With Hypercalcemia in an Infant: A Case Report [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#30
|
|||
|
|||
Ñïàñèáî âàì áîëüøîå,âñå ðàñïå÷àòàþ,èçó÷ó è ïîêàæó âðà÷àì. È åùå òàêîé âîïðîñ,äåëàëè ýëàñòîìåòðèþ íåñêîëüêî ðàç,â òîì ÷èñëå çà ïàðó äíåé äî áèîïñèè è òàì òîëüêî îäèí ðàç ïîêàçàëî F1, â îñòàëüíûõ ñëó÷àÿõ è òàêæå ïåðåä áèîïñèåé ñêàçàëè ÷òî äàæå íàìåêîâ íà ôèáðîç íåò. À ïî áèîïñèè F2-F3. Ýòî ìîæåò çàâèñåòü îò âçÿòîãî ó÷àñòêà? Ìîæåò ëè ýòî îçíà÷àòü ÷òî â áèîïàòå ôèáðîç,à â îñòàëûõ ó÷àñòêàõ îí ëèáî îòñóòñòâóåò ëèáî äåéñòâèòåëüíî ìàêñèìóì F1?
|